Lyra Therapeutics Files 8-K on Financials
Ticker: LYRA · Form: 8-K · Filed: Mar 21, 2024 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | 8-K |
| Filed Date | Mar 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
Lyra Therapeutics filed an 8-K detailing financial condition and results of operations.
AI Summary
On March 21, 2024, Lyra Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing provides an update on Lyra Therapeutics' financial status and operational results, which is crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a change in risk.
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Registrant
- March 21, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-39273 (identifier) — Commission File Number
- 480 Arsenal Way (address) — Principal Executive Offices
- Watertown, Massachusetts (location) — Principal Executive Offices Location
FAQ
What is the primary purpose of this 8-K filing for Lyra Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on Lyra Therapeutics, Inc.'s Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on March 21, 2024.
In which state is Lyra Therapeutics, Inc. incorporated?
Lyra Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Lyra Therapeutics, Inc.?
The principal executive office address for Lyra Therapeutics, Inc. is 480 Arsenal Way, Watertown, Massachusetts, 02472.
What is the Commission File Number for Lyra Therapeutics, Inc.?
The Commission File Number for Lyra Therapeutics, Inc. is 001-39273.
Filing Stats: 532 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-03-21 16:12:11
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share LYRA The Nasdaq
Filing Documents
- lyra-20240321.htm (8-K) — 40KB
- lyra-ex99_1.htm (EX-99.1) — 122KB
- 0000950170-24-034701.txt ( ) — 285KB
- lyra-20240321.xsd (EX-101.SCH) — 24KB
- lyra-20240321_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 21, 2024, Lyra Therapeutics, Inc. (the "Company") announced its financial results for the year ended December 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 of this Current Report on Form 8-K shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued on March 21, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lyra Therapeutics, Inc. Date: March 21, 2024 By: /s/ Jason Cavalier Jason Cavalier, Chief Financial Officer